| Q. |
What is Flavay™? |
| A. |
Flavay™ is a highly specialized, nutritional complex of pairs
and triples of a specific molecule called "flavan-3-ol,"
isolated from natural extracts, and that has been extensively tested
and examined clinically for biological antioxidant protection, collagen
strengthening, tissue rebuilding and other health producing outcomes.
[More...] |
| |
Top
 |
| Q. |
How safe is Flavay™? |
| A. |
After more than 50 years of human use, no adverse effects have been
observed. Furthermore, intensive biological, toxicological, pharmacological
and analytical research was conducted for the purpose of registering
it as a medicine in France and other countries in Europe. In one study,
daily doses of up to 35,000 mg for six months were determined to cause
no adverse effects. [More...] |
| |
Top
 |
| Q.
|
How does Flavay™ affect the liver? |
| A. |
Flavay™ helps protect hepatic capillaries (the smallest
blood vessels in the liver) from free radical damage and activates
liver antioxidant enzyme systems. A study of twenty patients with
cirrhosis of the liver showed that a daily intake of 300 mg of Flavay™
can help to decrease capillary fragility of the liver. |
| |
Top
 |
| Q.
|
Does Flavay™ have any contraindications? |
| A. |
No, Flavay™ has no known contraindications (conditions
under which it should not be used). Flavay™ is completely
safe and nontoxic. In fact, clinical trials have been conducted
in which pregnant women (troubled by varicose veins and other circulatory
problems in the legs) safely used Flavay™. [More...]
If you are taking anticoagulant medication, you should ask your
doctor whether you may also use Flavay™ as it will also decrease
the reactivity ("stickiness") of blood platelets. [More...] |
| |
Top
 |
| Q.
|
Should I consult with my doctor before taking Flavay™? |
| A. |
Yes, please consult your doctor before starting any course of
supplementation or diet change, particularly if you are currently
under medical care. If you have or suspect you may have a health
problem, you should consult your doctor.
If you are taking anticoagulant medication, you should ask your
doctor whether you may also use Flavay™ as it will also decrease
the reactivity ("stickiness") of blood platelets. [More...] |
| |
Top
 |
| Q. |
Can the active ingredients in Flavay™ be obtained in food? |
| A. |
Yes and No.
The active flavan-3-ol molecules in Flavay™ can be found
especially in the fibrous and woody parts of naturally-ripened,
raw fruits and vegetables, and in the skins of seeds, nuts and fruits.
Unfortunately, our fruits and vegetables are typically deficient
of these active polyphenol molecules due to our modern methods of
distributing food—which result in fruits and vegetables that
have been harvested while unripe. Another cause for deficiency is
cooking, which destroys the active polyphenols. What's more, the
skins of seeds, nuts and fruits are the parts of our food that we
generally discard or spit out.
Actually, the best "food" source is red wine. The active
principles in Flavay™ are at the center of the curious phenomenon
known as the "French Paradox." Red wine is a carrier of
these healthy polyphenols. So, why not just drink red wine to get
your daily dose of flavan-3-ol? Alcoholic beverages are not ideal
as dietary supplements due to potential abuse, dependency and toxicity
as a result of over consumption. And, while alcohol can compromise
liver function, Flavay™ actually helps protect hepatic
capillaries (the smallest blood vessels in the liver) from free
radical damage and activates liver antioxidant enzyme systems. The
point is that Flavay™ provides specific protection to the
liver, and red wine does not.
So, while drinking some red wine is a reasonably healthy for most
adults, the best way to guarantee a consistent daily intake of flavan-3-ol
polyphenols is in its pure, concentrated form—Flavay™. |
| |
Top
 |
| Q.
|
Is Flavay™ Patented? |
| A. |
Yes, there are many patents. In 1948 Dr. Jack Masquelier received
a French Patent which described a method to extract the active principles
in Flavay™ from the bark of the pinus Maritima. In
1970 Dr. Masquelier received another French Patent which described
an even more efficient extraction method of the active principles
from the seeds of the vitis vinifera grapes. On October
6, 1987 Dr. Masquelier was awarded U.S. Patent No. 4,698,360 to
describe the proanthocyanidins in Flavay™ for use as a powerful
antioxidant, "which has a radical scavenger effect."
"[A] method for preventing and fighting the
harmful biological effects of free radicals in the
organism of warm blooded animals and more especially human
beings, namely cerebral involution, hypoxia following
atherosclerosis,
cardiac or cerebral infarction, tumour promotion, inflammation,
ischaemia, alterations of the synovial liquid, collagen
degradation, among others. The method consists in administering
to said animals and especially to human beings an amount,
efficient against said effects, of a plant extract with
a proanthocyanidins content which has a radical scavenger
effect"Dr. Jack Masquelier, U.S. Patent
No. 4,698,360.
|
Flavay is the actual productused in the experimentsby
which Dr. Jack Masquelier established and patented the "radical
scavenger effect."
However, consumers need to know that the marketplace is full of
imitations, various “extracts” and derivative forms
of Dr. Masquelier’s scientifically proven and patented complex.
Unfortunately, many have used Dr. Masquelier’s name and research
in unauthorized ways to promote a myriad of derivations. In fact,
the other "leading brand" pine bark extract, compared
to Flavay™ below, is an offshoot derived from Dr. Masquelier's
authentic work and products. But, independent comparative testing
demonstrates that the initial qualifying research conducted on the
authentic products may not be automatically transferred to other
commercial products. [More...] |
| |
Top
 |
| Q.
|
Have proper research studies proven Flavay's™ effectiveness? |
| A. |
Yes, Flavay™ is backed by more than 50 years of research and
human use, patents for therapeutic uses and extensive testing for
safety. The original French and European brands (see Resivit™,
Endotelon™ and Flavan™
below) were registered in France as over-the-counter medications
and it has therefore been consumed in Europe under medical supervision
for decades with no reports of adverse side effects. [More...] |
| |
Top
 |
| Q.
|
"What is the difference between the terms, OPC
and polyphenol? In some cases it appears synonymous and in others
there appears to be a distinction. On some labels it will say OPC,
but in the supplement facts, it says grape seed extract (vitis
vinifera)
95% polyphenols. I am confused." |
| A. |
It's confusing because these
terms are used inaccurately
in the marketplace. "95% polyphenols" is a meaningless
expression in a scientific context. However, it does illustrate
a problem: In most cases, the following terms are used interchangeably
for commercial interests—or by mistake—and their differences
have truly lost all scientific meaning in the marketplace:
bioflavonoids and flavonoids,
oligomeric proanthocyanidins (OPCs or PCOs), and
polyphenols.
Therefore, when reading product labels, magazine articles and many
popular books, these scientific terms should be considered as generic
words and not scientific whatsoever. |
| |
Top
 |
| Q. |
Are OPCs (or,
proanthocyanidins) the same as "grape seed extract" or
"pine bark extract" products? |
| A. |
Yes (in the marketplace) and No
(in the scientific context).
Because of commercial
interests—or by mistake— the terms, OPCs and proanthocyanidins,
have truly lost all of their scientific meaning in the marketplace.
In most cases, suppliers and retailers confuse grape seed extracts
as being synonymous with opcs or proanthocyanidins.
However, the terms are not the
same in the scientific context. "Grape seed extract" is a
nonscientific term that has no specific meaning—other than crushed
seeds which can be toxic and oxidizing if not properly manufactured.
However, OPCs (short for oligomeric proanthocyanidins)
is the active ingredient that was discovered by Dr. Masquelier and
proven to have powerful antioxidant properties and other health
producing benefits.
It's important to note that
independent testing found no active OPCs in
a leading American brand of grape seed extract—even though it's
labeled and aggressively marketed as a branded OPC product. [More...]
|
| |
Top
 |
| Q. |
Is Flavay™ the same as "grape seed extract" or "pine
bark extract"? |
| A. |

Dr. Masquelier's original and only
industrial manufacturing plant, located in Gardonne, France.
|
No.
"Grape seed extract" is a vague, nonspecific term that really has
noscientific value. In fact, crude "grape seed extract" (and
"pine bark extract") imitations are virtually worthless to the
consumer without active and naturally-derived oligomeric
proanthocyanidins with antioxidant capacity. Some of these extract
products contain nothing more than
grape seeds or other plant parts which have been pulverized in a
food processor.
FlavayT, on the other hand, is a very specific molecular complex
which is scientifically defined and manufactured according to
the original process developed and patented by Dr. Jack
Masquelier in France, approved as an over-the-counter medicine in
France and manufactured under the control of French
Pharmaceutical inspection.
Independent
laboratory testing demonstrates that FlavayT scores the
highest as an antioxidant and as a
free radical scavenger, which is precisely the free radical
scavenging effect that Dr.
More...] |
| |
Top
 |
| Q. |
Is Flavay™ the same as OPCs (or
proanthocyanidins) in the
marketplace? |
| A. |
No.
OPCs (short for oligomeric proanthocyanidins)
is a term that covers many different and complex molecules. However,
due to commercial interests—or by mistake—the terms
"OPCs" and "proanthocyanidins" are often abused
and misunderstood and have therefore lost all of their scientific
meaning in the marketplace.
It's true that "OPCs" is the group of active principles
that is responsible for bringing the "grape seed extract"
category of products to fame. However, independent testing found
no active OPCs in a leading American
brand of grape seed extract, even though it's labeled and aggressively
marketed as a branded OPC product. [More...]
Consumers should also be aware that some manufacturers of grape
seed and pine bark extracts have devised ways to artificially boost
the proanthocyanidin numbers for their extracts in a test tube (in
vitro, which is outside the living body and in an artificial
environment ). However, there is no scientific research to show
whether the human body benefits from this artificial boost.
Flavay™ is unique. Flavay™ is derived from
the original manufacturing process developed and patented by Dr.
Jack Masquelier in France, which captures the naturally-derived
oligomeric proanthocyanidins from their plant sources. For well
over 50 years, each batch has been routinely and extensively tested
and analyzed to guarantee consistency, potency and purity.
Independent laboratory testing demonstrated that Flavay™
scores the highest as an antioxidant and as a free radical scavenger,
which is precisely the free radical scavenging effect that
Dr. Masquelier invented and claimed in U.S. Patent 4,698,360. [More...] |
| |
Top
 |
| Q. |
Do you have additional questions about Flavay™? |
| A. |
Click here to submit your question. |
| |
Top
 |
CLICK HERE TO SEE WHAT THE
CUSTOMERS ARE SAYING
|
[includes/foot_logos_flavay.html]
|
|
[includes/foot_links.html]
|
|
[includes/foot_disclaimer.html]
|
REFERENCES:
Top
|
Masquelier, J. Plant extract with a proanthocyanidins content
as a therapeutic agent having radical scavenging effect and use thereof.
U.S. Patent No. 4,698,360, 1987.
Masquelier, J. A lifetime devoted to OPC and Pycnogenols. Alfa Omega
Editrice,
Pub., 1996.
Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega
Editrice, Publishers,
1995.
Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats Publishing,
Inc., 1997.
Mindell, E., et al. Earl Mindells vitamin bible for the 21st century.
Warner Books, Inc., 1999.
Passwater, R.A. The antioxidants: the nutrients that guard your body. Keats
Publishing, Inc., 1985.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants.
Keats Publishing, Inc., 1995.
Facino RM, et al. Free radical scavenging action and anti-enzyme activities
of procyanidines from Vitis vinifera. A mechanism for their capillary protective
action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant to the
action of mammalian collagenase. Experientia, 37: 221-223, 1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres
procyanidoliques.
Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains
flavonoides.
A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques
totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres
flavonoliques.
Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de laction des
oligomeres procyanidoliques sur des cellules mesenchymateuses en culture.
Ii lattachment des fibres elastiques aux cellules. (Study of the effect
of procyanidolic oligomers on mesenchymal cells in culture. Ii attachment
of elastic fibers to the cells.) Pat Biol, (30)6:601-7, 1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and crystal
structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3,
4.4, 5.7-Hexahydroxyflavan] dihydrate, and comparison of its
heterocyclic ring conformation in solution and the solid state. Journal
of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free radicals.
Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and
b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990.
pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different procyanidins
from grape seeds. Presented at a symposium, Free radicals in biotechnology
and medicine. Royal Society Of Chemistry, London January 1990, pp.
79-80.
Bauman, J., Wurm, G., Bruchhausen, F. Hemmung der prostagladinsynthetase
durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften
Arch Pharm, (Weinheim) 313 (1980) pp. 330-337.
Lombard, J., et al. The brain wellness plan. Kensington Pub. Corp., 1998.
Braverman, E., et al. The healing nutrients within: in facts, findings and
new research. Keats, 1987.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme activities
of procyanidines from vitis vinifera. A mechanism for their capillary protective
action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with catechin
becomes resistant to the action of mammalian collagenase. Experientia, 37:
221-223, 1981.
Masquelier, J. Procyanidolic oligomers. J Parums Cosm
Arom, 95: 89-97, 1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies that binding
of pycnogenols to elastin affects its rate of degradation by elastases.
Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985.
Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers extracted
from vitus vinifera l. in the rat. European Journal of Drug
Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30.
Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging activity
of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo
and in vitro study. Cosmetology Department & S Biovectors, Ramonville
St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting
enzyme by flavanolic compounds: in vitro and in vivo studies. Planta
Medica,
May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez lanimal-oedenme de la patte. Sanofi Res Toul Cedex Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez lanimal-activite aniagoniste vis-a-vis des mediateurs de linflamation.
Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance
capillaire,
spontanement ou artificiellement diminuee par laction dune substance
capillaro-toxique chez des personnes agees--action benefique dun agnet
actif sur la micro-circulation: lEndotelon. Inform. Therapeut. 1980.
pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude dun
microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990.
Lagrue, G., Olivier-Martin, F., Grillot, A. Etude des effets des oligomeres
du procyanidol sur las resistance capillaire dand lhypertension arterielle
et certaines nephropathies. Sen. Hosp. Paris 18-25 Septembre, 1981.
Beylot, C., Bioulac, P. Essai therapeutique dun angioprotecteur
peripherique,
lEndotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24,
1980.
Lesbre, F.X., Tigaud, J.D. Effect de lEndotelon sur lindice
de fragilite capillaire dan une population specifique: les sujets
cirrhotiques. Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres inferieurs
par un microangioprotecteur lEndotelon. Bordeaux Med, 11:685-8, 1981.
Delacroix, P. Etude en double aveugle de lEndotelon dans linsuffisance
veineuse chronique. Therapeutique, la Revue de Medicine, (27-28) Sept. 1981.
pp. 1793-1802.
Thebaut, J.F, Thebaut, P., Vin, F. Etude de lEndotelon dand les manifestations
fonctionnelles de linsuffisance veineuse peripherique-resultats dune
etude en double aveugle portant sur 92 patients. Gazette Medicale,
(92)1, 1985. pp. 96-100.
Wegrowski, J., Robert, A.M., Maczar, M. The effect of procyanidolic oligomers
on the composition of normal and hypercholesterolemic rabbit aortas.
Biochem. Pharmacol, (33)21. 1984. pp. 3491-3497.
Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and arachidonate
metabolism in platelets by procyanidins. Prostagland Leukotri Essent Fatty
Acids, 38:181-8, 1989.
Masquelier, J. Pycnogenols: recent advances in the therapeutical activity
of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant
Research and Journal of Natural Products, July 1980 pp. 243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury: implications
in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106.
Masquelier, J. Les procyanidols du vin leur role dans lalcoolisme.
pp. 88-93.
Gazave, J.M. Notions recentes sur les capillaires
unpub. bulletin
from the Laboratoire De Physiologie Patholigie pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation and
atherothrombosis.
Office International Vigne et du Vin, Nutrition and Health Unit, Paris France;
Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131),
1999.
Blaszo, G. Gabor, M. Oedema-inhibiting effect of
procyanidin. Acta Physiologica
Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur lhyalaluronidase.
Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en
gynecologie. Essai
Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P Une Etude Exemplaire Pour Un
Phlebotrope: letude EIVE. Unpub., pp. 77-83.
Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres
procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye.
Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di Ferrante, N. Collagen treated with (+)
-catechin becomes resistant to the action of mammalian
collagenase.
Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col.
of Med., Houston TX. 28, May, 1980.
Gendre, P., Laparra, J., Barraud, E. Effect protecteur des oligomeres
procyanidoliques sur le lathyrisme experimental chez le rat. Ann.
Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal circulation.
Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr.
Opthalmol,
(11)5:453-460, 1988.
Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and dazzling:
use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4,
177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside oligomers
effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93,
1988.
Saracco, J.B., Estachy, G.M. Etude d lEndotelon en
opthalmologie.
Gaz Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies.
Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr.
Opthalmol, 11:453,
1988.
Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et
O.P.C. Bordeaux Medicale,
(16)11. pp. 1467-74, 1978.
Soyeux, A. et al. Endotelon. Diabetic retinopathy and
hemorheology. Bull
Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. Les oligomeres procyanidoliques dans le traitement de
la fragilite capillaire et de la retinopathie chez les diabetiques. A propos
de 26 cas. Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a letude des oligomeres procyanidoliques:
Endotelon, dans la retinopathie diabetique (a propos de 30 observations).
Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results of a double-blind
study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5,
1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism in
rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels.
Angiologica,
9:355-374, 1972.
Havsteen, B. Flavonoids, a class of natural products of high pharmacological
potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J. Berkhauser
Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977.
Masquelier, J. Action protectrice du vin sur lulcere
gastrique. Resultats,
p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by flavonoids
and bioflavonoids. Planta Medica, 5116-20, 1985.
Packer, L., et al. The antioxidant miracle: your complete plan. John Wiley
& Sons, Inc., 1999.
Shaw, R. How [Australian] PycnoGenol [MASQUELIERs®] Helps Sports
People.
Masquelier, J. Procyanidolic oligomers
(leucocyanidins). Parfums Cosmet
Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques (Endotelon) dans le traitement des lymphoedemes
post-therepeutiques de members
superieurs. Symposium Satellite, Congres International dAngiologie,
Toulouse, France, 4-7 Oct. 1989.
Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine during 2 weeks
of intense training. Abstract submitted to national meeting of the Amer
College of Sports Medicine, June 1998.
Monteleone, P., Maj, M., Beinat, L.,
Natale, M., Kemali, D. Blunting by
chronic phosphatidylserine administration of the stress-induced activation
of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm
43: 385388, 1992.
Fahey, T.D., et al. The hormonal and perceptive effects of phosphatidylserine
administration during two weeks of resistive exercise-induced overtraining.
Bio of Sport 15(3):135-44, 1998.
Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres procyanidoliques
sur le cobaye carence en vitamin c. Tavaux Originaux, University of Bordeaux,
1976.
Masquelier, J. Action comparee de divers facteurs vitaminiques p sur loxydation
de lacide ascorbique par les ions cuivriques. Bull. de la Societe
de Chimie Biologique XXXIII (3-4) 1951. pp. 302-304.
Masquelier, J. Action comparee de divers facteurs vitaminiques p sur lacide
ascorbique-oxydase. Bull. de la Societe de Chimie Biologique XXXIII (3,4)
1951. pp.304-306
Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T.,
Nonaka, G., Mishioka,
I. Inhibitory effects of tannins on hyaluronidase activation and on
the degranulation from rat mesentery mast cells. Chem. Pharm. Bull.
33(11)1985. 5079-5082.
Reiman, H.J., Lorenz, M., Fischer, R.,
Frolich, H., Meyer, J. Histamine
and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress
ulcer formulation by (+)-catechin, an inhibitor of specific histidine decarboxylase
in vitro. Dirkhauser Verlag,Vol. 7/1, 1977.
Pariente, J.J. Parientl-Amsellem, J. Les oedemes
post-traumatoqies
chez le sportif: essai controle de lEndothelon. Actualite Therapeutique
90(3) 2/11 1983 pp. 231-235.
Masquelier, J., et al. Flavonoids et Pycnogenols Int J Vit Nut
Res, (49)3:307-311, 1979.
Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem. Toxicol.
25(2):135-9, 1987.
Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica
Report, 1971.
Laparra, J., et al., Acta Therapeutica, 4:233, 1978.
Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow cells
of the mouse with Pycnogenol. Cytotest Cell Research GmbH & Co., projects
143010 & 143021; Feb. 1989.
Acute and chronic toxicity tests. International Bio-Research, Inc., Hanover,
Germany, 1967-1971.
Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content in vegetable
extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux,
129:51-65, 1990. |
|